Metacognitive therapy, when incorporated in cardiac rehabilitation, is useful for managing depression and anxiety in patients with cardiovascular disease (CVD), according to the results of the PATHWAY study. This approach also confers benefits for trauma symptoms, beliefs about thinking, and unhelpful thinking styles.
Patients with depression, antidepressant or antipsychotic medication use, insomnia, and anxiety disorders are more likely to develop type 2 diabetes (T2D) than those without these exposures, according to a study.
The second-generation antipsychotic amisulpride performs well in the treatment of depression and associated symptoms in individuals with a major mental health disorder, with efficacy and tolerability profiles similar to those of selective serotonin reuptake inhibitors and tricyclic antidepressants, as suggested in a meta-analysis of randomized controlled trials.
Among young people type 1 diabetes (T1D), those with coeliac disease (CD) are also more likely to have depression, according to a study, suggesting that the double burden of T1D and CD may increase susceptibility to depression.